In NSCLC, overexpression of AURKA was regarded as a poor prognosis and therefore AURKA inhibitors could not only cause G2/M arrest of cancer cells but also lead to the significant autophagy and enhance the anticancer activity of clinical medicine (Katayama and sen., 2010). This evidence concerns the gene AURKA and non-small cell lung carcinoma.